Treatment Information

Back

Lung Cancer treatment details. Chemotherapy, Biologic therapy.

Catalan Institute of Oncology, Barcelona, Spain.

Survival: monthsCountry:Spain
Toxiciy Grade:4City/State/Province:Barcelona
Treatments:Chemotherapy, Biologic therapyHospital:Catalan Institute of Oncology
Drugs:Journal:Link
Date:Feb 2008

Description:

Patients: This phase II study involved eighty-six patients with advanced non-small-cell lung cancer that expressed EGFR. These patients ranged in age from 33 to 74 years old, and there were about three times as many men as women in this study.

Treatment: Patients were treated with the biological therapy cetuximab (a monoclonal antibody) and the chemotherapy drugs vinorelbine and cisplatin, or the chemotherapy drugs only.

Toxicity: Grade 4 asthenia, respiratory symptoms, vomiting, and infection were reported. Grade 4 neutropenia was reported in 37% of patients receiving cisplatin and vinorelbine, and in 50% of patients treated with these drugs and cetuximab. Grade 3 and grade 4 neutropenia were more common in the group receiving cetuximab.

Results: The median overall survival was 8.3 months for patients treated with cetuximab, cisplatin and vinorelbine, and 7.3 months for those receiving only chemotherapy (cisplatin and vinorelbine).

Correspondence: Dr. R. Rosell



Back